116 related articles for article (PubMed ID: 20392639)
1. Discovery of 2-chloro-N-((4,4-difluoro-1-hydroxycyclohexyl)methyl)-5-(5-fluoropyrimidin-2-yl)benzamide as a potent and CNS penetrable P2X7 receptor antagonist.
Chen X; Pierce B; Naing W; Grapperhaus ML; Phillion DP
Bioorg Med Chem Lett; 2010 May; 20(10):3107-11. PubMed ID: 20392639
[TBL] [Abstract][Full Text] [Related]
2. Discovery of N-(5,6-diarylpyridin-2-yl)amide derivatives as potent and selective A(2B) adenosine receptor antagonists.
Eastwood P; Gonzalez J; Paredes S; Nueda A; Domenech T; Alberti J; Vidal B
Bioorg Med Chem Lett; 2010 Mar; 20(5):1697-700. PubMed ID: 20137946
[TBL] [Abstract][Full Text] [Related]
3. Characterization of N-(adamantan-1-ylmethyl)-5-[(3R-amino-pyrrolidin-1-yl)methyl]-2-chloro-benzamide, a P2X7 antagonist in animal models of pain and inflammation.
Broom DC; Matson DJ; Bradshaw E; Buck ME; Meade R; Coombs S; Matchett M; Ford KK; Yu W; Yuan J; Sun SH; Ochoa R; Krause JE; Wustrow DJ; Cortright DN
J Pharmacol Exp Ther; 2008 Dec; 327(3):620-33. PubMed ID: 18772321
[TBL] [Abstract][Full Text] [Related]
4. Phenylaminopyrimidines as inhibitors of Janus kinases (JAKs).
Burns CJ; Bourke DG; Andrau L; Bu X; Charman SA; Donohue AC; Fantino E; Farrugia M; Feutrill JT; Joffe M; Kling MR; Kurek M; Nero TL; Nguyen T; Palmer JT; Phillips I; Shackleford DM; Sikanyika H; Styles M; Su S; Treutlein H; Zeng J; Wilks AF
Bioorg Med Chem Lett; 2009 Oct; 19(20):5887-92. PubMed ID: 19762238
[TBL] [Abstract][Full Text] [Related]
5. Discovery of N-(3-(morpholinomethyl)-phenyl)-amides as potent and selective CB2 agonists.
Worm K; Weaver DG; Green RC; Saeui CT; Dulay DM; Barker WM; Cassel JA; Stabley GJ; DeHaven RN; LaBuda CJ; Koblish M; Brogdon BL; Smith SA; Dolle RE
Bioorg Med Chem Lett; 2009 Sep; 19(17):5004-8. PubMed ID: 19646869
[TBL] [Abstract][Full Text] [Related]
6. Discovery and optimization of RO-85, a novel drug-like, potent, and selective P2X3 receptor antagonist.
Brotherton-Pleiss CE; Dillon MP; Ford AP; Gever JR; Carter DS; Gleason SK; Lin CJ; Moore AG; Thompson AW; Villa M; Zhai Y
Bioorg Med Chem Lett; 2010 Feb; 20(3):1031-6. PubMed ID: 20045645
[TBL] [Abstract][Full Text] [Related]
7. Piperazinyl-glutamate-pyrimidines as potent P2Y12 antagonists for inhibition of platelet aggregation.
Parlow JJ; Burney MW; Case BL; Girard TJ; Hall KA; Hiebsch RR; Huff RM; Lachance RM; Mischke DA; Rapp SR; Woerndle RS; Ennis MD
Bioorg Med Chem Lett; 2009 Nov; 19(21):6148-56. PubMed ID: 19796941
[TBL] [Abstract][Full Text] [Related]
8. Discovery of potent and selective adamantane-based small-molecule P2X(7) receptor antagonists/interleukin-1beta inhibitors.
Furber M; Alcaraz L; Bent JE; Beyerbach A; Bowers K; Braddock M; Caffrey MV; Cladingboel D; Collington J; Donald DK; Fagura M; Ince F; Kinchin EC; Laurent C; Lawson M; Luker TJ; Mortimore MM; Pimm AD; Riley RJ; Roberts N; Robertson M; Theaker J; Thorne PV; Weaver R; Webborn P; Willis P
J Med Chem; 2007 Nov; 50(24):5882-5. PubMed ID: 17963373
[TBL] [Abstract][Full Text] [Related]
9. The discovery of novel N-(2-pyrimidinylamino) benzamide derivatives as potent hedgehog signaling pathway inhibitors.
Xin M; Wen J; Tang F; Tu C; Shen H; Zhao X
Bioorg Med Chem Lett; 2013 Dec; 23(24):6777-83. PubMed ID: 24176396
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and structure-activity relationships of a series of (1H-pyrazol-4-yl)acetamide antagonists of the P2X7 receptor.
Chambers LJ; Stevens AJ; Moses AP; Michel AD; Walter DS; Davies DJ; Livermore DG; Fonfria E; Demont EH; Vimal M; Theobald PJ; Beswick PJ; Gleave RJ; Roman SA; Senger S
Bioorg Med Chem Lett; 2010 May; 20(10):3161-4. PubMed ID: 20399651
[TBL] [Abstract][Full Text] [Related]
11. Discovery of N-substituted pyridinones as potent and selective inhibitors of p38 kinase.
Selness SR; Devraj RV; Monahan JB; Boehm TL; Walker JK; Devadas B; Durley RC; Kurumbail R; Shieh H; Xing L; Hepperle M; Rucker PV; Jerome KD; Benson AG; Marrufo LD; Madsen HM; Hitchcock J; Owen TJ; Christie L; Promo MA; Hickory BS; Alvira E; Naing W; Blevis-Bal R
Bioorg Med Chem Lett; 2009 Oct; 19(20):5851-6. PubMed ID: 19751974
[TBL] [Abstract][Full Text] [Related]
12. Optimization of the physicochemical and pharmacokinetic attributes in a 6-azauracil series of P2X7 receptor antagonists leading to the discovery of the clinical candidate CE-224,535.
Duplantier AJ; Dombroski MA; Subramanyam C; Beaulieu AM; Chang SP; Gabel CA; Jordan C; Kalgutkar AS; Kraus KG; Labasi JM; Mussari C; Perregaux DG; Shepard R; Taylor TJ; Trevena KA; Whitney-Pickett C; Yoon K
Bioorg Med Chem Lett; 2011 Jun; 21(12):3708-11. PubMed ID: 21565499
[TBL] [Abstract][Full Text] [Related]
13. Part 2: Structure-activity relationship (SAR) investigations of fused pyrazoles as potent, selective and orally available inhibitors of p38alpha mitogen-activated protein kinase.
Wurz RP; Pettus LH; Henkle B; Sherman L; Plant M; Miner K; McBride HJ; Wong LM; Saris CJ; Lee MR; Chmait S; Mohr C; Hsieh F; Tasker AS
Bioorg Med Chem Lett; 2010 Mar; 20(5):1680-4. PubMed ID: 20138761
[TBL] [Abstract][Full Text] [Related]
14. Identification and SAR of novel diaminopyrimidines. Part 2: The discovery of RO-51, a potent and selective, dual P2X(3)/P2X(2/3) antagonist for the treatment of pain.
Jahangir A; Alam M; Carter DS; Dillon MP; Bois DJ; Ford AP; Gever JR; Lin C; Wagner PJ; Zhai Y; Zira J
Bioorg Med Chem Lett; 2009 Mar; 19(6):1632-5. PubMed ID: 19231178
[TBL] [Abstract][Full Text] [Related]
15. Discovery of 8-azabicyclo[3.2.1]octan-3-yloxy-benzamides as selective antagonists of the kappa opioid receptor. Part 1.
Brugel TA; Smith RW; Balestra M; Becker C; Daniels T; Hoerter TN; Koether GM; Throner SR; Panko LM; Folmer JJ; Cacciola J; Hunter AM; Liu R; Edwards PD; Brown DG; Gordon J; Ledonne NC; Pietras M; Schroeder P; Sygowski LA; Hirata LT; Zacco A; Peters MF
Bioorg Med Chem Lett; 2010 Oct; 20(19):5847-52. PubMed ID: 20727752
[TBL] [Abstract][Full Text] [Related]
16. Discovery, synthesis and SAR of azinyl- and azolylbenzamides antagonists of the P2X₇ receptor.
Subramanyam C; Duplantier AJ; Dombroski MA; Chang SP; Gabel CA; Whitney-Pickett C; Perregaux DG; Labasi JM; Yoon K; Shepard RM; Fisher M
Bioorg Med Chem Lett; 2011 Sep; 21(18):5475-9. PubMed ID: 21782426
[TBL] [Abstract][Full Text] [Related]
17. The identification of a series of novel, soluble non-peptidic neuropeptide Y Y2 receptor antagonists.
Lunniss GE; Barnes AA; Barton N; Biagetti M; Bianchi F; Blowers SM; Caberlotto LL; Emmons A; Holmes IP; Montanari D; Norris R; Puckey GV; Walters DJ; Watson SP; Willis J
Bioorg Med Chem Lett; 2010 Dec; 20(24):7341-4. PubMed ID: 21074426
[TBL] [Abstract][Full Text] [Related]
18. Identification and SAR of novel diaminopyrimidines. Part 1: The discovery of RO-4, a dual P2X(3)/P2X(2/3) antagonist for the treatment of pain.
Carter DS; Alam M; Cai H; Dillon MP; Ford AP; Gever JR; Jahangir A; Lin C; Moore AG; Wagner PJ; Zhai Y
Bioorg Med Chem Lett; 2009 Mar; 19(6):1628-31. PubMed ID: 19231180
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and structure-activity relationships of pyrazolodiazepine derivatives as human P2X7 receptor antagonists.
Lee JY; Yu J; Cho WJ; Ko H; Kim YC
Bioorg Med Chem Lett; 2009 Nov; 19(21):6053-8. PubMed ID: 19800793
[TBL] [Abstract][Full Text] [Related]
20. Novel sulfamoyl benzamides as selective CB(2) agonists with improved in vitro metabolic stability.
Sellitto I; Le Bourdonnec B; Worm K; Goodman A; Savolainen MA; Chu GH; Ajello CW; Saeui CT; Leister LK; Cassel JA; Dehaven RN; Labuda CJ; Koblish M; Little PJ; Brogdon BL; Smith SA; Dolle RE
Bioorg Med Chem Lett; 2010 Jan; 20(1):387-91. PubMed ID: 19919895
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
